Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Arthritis Rheum. 2008 Nov;58(11):3485–3497. doi: 10.1002/art.23954

Figure 2.

Figure 2

Trabecular bone architectural changes with glucocorticoid (GC) excess (days 1−56) and after treatments with GC+Ris or GC+PTH, days 29−56. Upper panel: unstained LVB sections taken at day 56. Lower two panels: bone histomorphometry measurements performed in the trabecular bone regions of the LVB. GC excess decreased bone mass and induced thinner trabeculae with less mineralizing (fluorescent labeling) surface but higher osteoclast surface than the placebo control (PL). GC+PTH treatment induced higher bone mass and thicker trabeculae than PL and GC and had higher mineralizing surface and bone formation rate than PL and GC groups. Also GC+PTH had double-labeled surface surrounding some osteocytes just below the base of the remodeling cavity (arrow). GC+Ris had higher bone mass and trabecular thickness as compared to the GC only group but these were lowered than the PL group with lower bone formation rate and less osteoclast surface. *= p < 0.05 from placebo; #= p < 0.05 from GC.